Inclusion Criteria:  Male or female subjects who are more than 18 years of age, on the day of signing informed consent Documented diagnosis of IBD, established on the basis of standard clinical, endoscopic and/or histological criteria. CD or UC remission defined per clinical assessment as a Harvey Bradshaw Index (HBI) score ≤4 for CD patients and a Partial Mayo Score (PMS) < 2 with each sub-score of 1 or less for UC and/or according to ECCO classification within previous 3 months Currently treated with IV vedolizumab Patients agreeing to switch from IV to SC formulation  Receiving or not the concomitant following drugs (but must remain on stable dose for 12 weeks):  Oral 5-aminosalicylates (5ASA) compounds or rectal formulations of 5ASA provided the dose to be stable at least 4 weeks before switching Azathioprine, 6-Mercaptopurine or methotrexate provided the dose has been stable for 4 weeks prior to inclusion • Each patient is required to provide written informed consent in order to be included in the study  Exclusion Criteria:  Current use of adalimumab, infliximab, golimumab or ustekinumab Current use of JAK inhibitors or S1P modulators Current use of steroids or within the last three months for IBD Treatment with any investigational agent in the past 30 days or five half-lives prior to the screening visit (whichever is longer) Active clinically significant infection or HIV, Hep B, Hep C, untreated tuberculosis Female subjects with pregnancy or breastfeeding